CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D019964: Mood Disorders NIH

(Synonyms: Mood Disorder, Mood Disorders)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1106 Questionnaire to study the psychological impact of confinement Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003866 Depressive Disorder NIH 0.45
D003863 Depression, NIH 0.27

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000716 Depressivity HPO 0.45

There is one clinical trial.

Clinical Trials


1 Descriptive Study of the PSYchological Impact of CONFinement Measures in Subjects With Mood Disorders : PsyConf

Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom .It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms. Poor social contacts and history of psychiatric disorders are factors increasing the negative psychological impact of confinement. Patients with psychiatric disorders are therefore particularly vulnerable during quarantine. Only one study has reported that history of psychiatric disorder was associated with a higher risk of anxiety and anger at 4 - 6 months after the end of quarantine. Since March 17th, 2020 the French government has implemented national containment measures due to the Covid-19 epidemic. This situation has led to a reorganization of care as requested on March 22nd, 2020 in the recommendations applicable to the organization of care in psychiatric services: priority to telephone contacts and teleconsultations by multiplying contacts and assessments. As part of the telephone contacts that are now part of the recommended care, patients are systematically interviewed on the impact of the confinement situation on their psychological well-being with self-questionnaires used in the daily clinical practice. Assessing the negative psychological impact in patients with a psychiatric history is essential to better deploy post-confinement management. This assessment will provide preliminary indicators for the appropriate organization of care.

NCT04374643 Depression, Unipolar COVID 19 Other: Questionnaire to study the psychological impact of confinement
MeSH:Depression Depressive Disorder Mood Disorders
HPO:Depressivity

Primary Outcomes

Description: depressive symptomatology with Patient Health Questionnaire

Measure: Depressive Symptomatology

Time: during confinement

Secondary Outcomes

Description: depressive symptomatology with Patient Health Questionnaire

Measure: Depressive Symptomatology

Time: post-confinement : 15 days, 3 months, 6 months

Other Outcomes

Description: Psychological pain : likert scale

Measure: Psychological pain

Time: confinement

Description: quality of sleep assessed with Insomnia Seveity Index

Measure: sleep

Time: confinement

Description: quality of sleep assessed with Insomnia Seveity Index

Measure: sleep

Time: post-confinement (15 days, 3 months, 6 months)

Description: anxiety intensity assessed by Generalized Anxieety Disorder

Measure: anxiety

Time: confinement

Description: anxiety intensity assessed by Generalized Anxieety Disorder

Measure: anxiety

Time: post-confinement (15 days, 3 months, 6 months)

Description: psychological pain : likert scale

Measure: psychological pain

Time: post-confinement (15 days, 3 months, 6 months)

Description: psychological pain : likert scale

Measure: physical pain

Time: confinement

Description: psychological pain : likert scale

Measure: physical pain

Time: post-confinement (15 days, 3 months, 6 months)

Description: staxi state scale

Measure: anger

Time: confinement

Description: staxi state scale

Measure: anger

Time: post-confinement (15 days, 3 months, 6 months)

Description: Assessed by the Stressful Event Impact Scale - Horowitz

Measure: Stressful Event Impact

Time: confinement

Description: Assessed by the Stressful Event Impact Scale - Horowitz

Measure: Stressful Event Impact

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative psychotropic drugs consumption

Measure: Use of psychotropic drugs

Time: confinement

Description: declarative psychotropic drugs consumption

Measure: Use of psychotropic drugs

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: Tobacco consumption

Time: confinement

Description: declarative consumption

Measure: Tobacco consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: alcohol consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: alcohol consumption

Time: confinement

Description: declarative consumption

Measure: Illicit substances consumption

Time: confinement

Description: declarative consumption

Measure: Illicit substances consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: LOT-R questionnaire

Measure: orientation of life

Time: confinement

Description: LOT-R questionnaire

Measure: orientation of life

Time: post-confinement (15 days, 3 months, 6 months)


HPO Nodes